Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Axsome Therapeutics wins FDA for novel antidepressant Auvelity

By Brian Buntz | August 19, 2022

AxsomeThe biopharma Axsome Therapeutics (Nasdaq:AXSM) has won FDA approval for Auvelity (dextromethorphan HBr-bupropion HCl) extended-release tablets for treating major depressive disorder (MDD) in adults.

Auvelity is the only rapid-acting oral medicine for MDD with labeling describing statistically significant antidepressant efficacy at one week. Clinical trial data also show that the drug maintains efficacy at week 6. 

Axsome Therapeutics concludes that the drug represents the first new mode of action for MDD in more than 60 years. 

The company also notes that the drug is the only oral N-methyl D-aspartate (NMDA) receptor antagonist approved for MDD. 

“It is important to highlight that MDD is a serious, chronic, disabling and even life-threatening condition with very high rates of morbidity and mortality,” said NYU Langone psychiatrist Dr. Dan Iosifescu in an Axsome webinar. “The morbidity seen in patients with MDD includes profound distress, inability to work and impaired social functioning.” 

While the prevalence of depression has increased during the pandemic, many patients remain frustrated with currently available treatment options. Almost two-thirds, 63%, fail to achieve remission after initial pharmacotherapy, Iosifescu said. 

According to Axsome research, 78% of MDD patients were frustrated with at least one treatment for the condition. 

One of the most popular classes of antidepressants, SSRIs, can take between six to eight weeks to be effective. Many SSRIs have efficacy that is marginally better than placebo. 

“Very importantly, all currently approved oral agents for major depressive disorder work primarily through monoaminergic mechanisms,” Iosifescu said. “This is a very important point to consider, as it may explain the high rates of inadequate response with current treatments for major depressive disorder.”

Auvelity is an oral N-methyl-D-aspartic acid (NMDA) receptor antagonist, sigma-1 receptor agonist and glutaminergic-modulating treatment. 

In a placebo-controlled Phase 3 study, the drug was generally well tolerated and led to statistically significant reductions in the Montgomery-Asberg Depression Rating Scale (MADRS). 

Auvelity has patent protection extending out to at least 2037.  

While the drug has a proprietary formulation, the two compounds in Auvelity are not new. 

Dextromethorphan is a widely used OTC cough suppressant. 

Bupropion is a smoking-cessation drug with a history of use as an antidepressant. With the trade name Wellbutrin, the drug won FDA approval as an antidepressant in 1985. 

Auvelity aims to commercialize the drug in the fourth quarter of 2022. 

The company has yet to determine the pricing of the drug. 

AXSM shares jumped 40.35% to $59.55. 


Filed Under: Psychiatric/psychotropic drugs
Tagged With: Auvelity, Axsome
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Muse Clinic: Innovating with Psychedelics and Neurotechnology
Can LSD break the 20-year drought in anxiety treatment?
MAPS
FDA rejection of MDMA and journal retractions jolt psychedelic therapy research
MDMA
Experts endorse MDMA-assisted therapy for PTSD amid FDA adcomm setback
depression sadness and loneliness concept art illustration of wo
Precision psychiatry: A data-driven approach to personalized depression treatment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE